Print this page

Business Development 1999-2008

€ million

1999

2000

2001

2002

2003

2004

2005

2006¹

2007²

2008

Change vs. 2007 in %

1	In order to harmonize accounting practices, as of 2006 the way in which certain customer rebates in the Pharmaceuticals business sector are reported has been changed.
2	Following its acquisition, the Swiss biopharmaceutical company Serono was integrated with the Ethicals division into Merck Serono in 2007.
3	The Generics division was sold in October 2007 and is thus reported as a Discontinued Operation. All revenue, profit and employee figures have been adjusted for 2006 and 2007.
4	Business was divested.
5	Still including Discontinued Operations (Generics) in 2006 and 2007.

Total revenues³

5,433

6,896

7,697

7,497

7,343

5,994

5,865

4,460

7,057

7,558

7.1

Pharmaceuticals³

2,924

3,035

3,469

3,244

3,438

3,579

3,885

2,314

4,877

5,428

11

1,675

1,929

2,215

1,833

1,528

1,597

1,797

1,914

4,458

4,987

12

Generics

657

790

935

1,096

1,584

1,625

1,712

–

–

–

–

Consumer Health Care

263

299

319

315

327

357

376

400

420

442

5.2

Imaging⁴

329

17

–

–

–

–

–

–

–

–

–

Chemicals

1,398

1,677

1,720

1,788

1,705

1,694

1,905

2,112

2,150

2,123

–1.3

Liquid Crystals

174

312

297

383

443

589

741

895

916

877

–4.2

Performance & Life Science Chemicals

1,089

1,173

1,207

1,213

1,082

1,105

1,163

1,217

1,235

1,246

0.9

Electronic Chemicals⁴

135

192

216

192

181

–

–

–

–

–

–

Laboratory Distribution⁴

1,262

2,374

2,754

2,711

2,427

582

–

–

–

–

–

Intragroup sales

–151

–190

–246

–246

–228

–62

–

–

–

–

–

Corporate and Other

–

–

–

–

–

200

76

34

29

7

–77

Generics (Discontinued Operations)³

–

–

–

–

–

–

–

1,824

1,395

0

–

Operating result³

659

746

877

616

736

776

883

799

976

1,131

16

Pharmaceuticals³

498

455

581

272

389

391

454

217

417

655

57

Chemicals

114

247

204

260

316

420

492

641

631

558

–12

Laboratory Distribution⁴

47

44

92

84

79

21

–

–

–

–

–

Corporate and Other

0

0

0

0

–48

–56

–63

–60

–72

–81

14

Generics (Discontinued Operations)³

–

–

–

–

–

–

–

307

189

0

–

Earnings before interest and tax (EBIT)³

581

747

1,286

559

538

1,044

956

1,031

200

731

–

EBIT before depreciation and amortization (EBITDA)³

900

1,184

1,694

985

1,008

1,419

1,245

1,334

1,858

1,947

4.8

Profit before tax³

440

524

1,078

412

423

961

893

982

–111

575

–

Profit after tax⁵

235

262

655

215

218

672

673

1,001

3,520

379

–89

Free cash flow⁵

–1,081

324

664

441

442

1,889

657

–1,073

–1,473

438

–

Capital expenditure on property, plant and equipment⁵

359

427

470

377

281

234

268

253

283

395

40

Research and development³

498

546

577

608

605

599

713

615

1,028

1,234

20

7,845

8,235

8,255

7,511

6,982

5,754

7,281

8,102

14,922

15,645

4.8

Net equity

1,870

1,947

2,336

2,054

2,363

2,800

3,329

3,807

8,688

9,563

10

Employees (number as of December 31)³

32,721

33,520

34,294

34,504

34,206

28,877

29,133

25,531

30,968

32,800

5.9

Return on sales³ (ROS) in % (ROS: Operating result/Total revenues)

12.3

11.1

11.6

8.3

10.2

13.2

15.3

17.9

13.8

15.0

Earnings per share in €

1.32

1.44

3.66

1.18

1.15

3.47

3.40

5.07

16.21

1.69

–

Dividend per share in €

0.85

0.90

0.95

1.00

0.80

0.80

0.85

0.90

1.20

1.50

–

One-time bonus per share in €

–

–

–

–

–

0.20

–

0.15

2.00

–

–

© Merck KGaA, Darmstadt, Germany, Last update 18.02.2009